Zocor

[simvastatin]

After the LDL-C goal has been achieved, if the TG is still 200 mg/ dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/ dL higher than LDL-C

goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is 130 mg/ dL (see NCEP Treatment Guidelines, above). The NCEP classification of cholesterol levels in pediatric patients with a familial history of either hypercholesterolemia or premature cardiovascular disease is summarized in Table 7.

TABLE 7
NCEP Classification of Cholesterol Levels in Pediatric Patients
with a Familial History of Either HeFH or Premature CVD

Text Continues Below

---

Category Total-C (mg/ dL) LDL-C (mg/ dL)
Acceptable <170 <110
Borderline 170-199 110-129
High 200 130

Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. ZOCOR is indicated to reduce elevated LDL-C and TG levels in patients with Type IIb hyperlipidemia (where hypercholesterolemia is the major abnormality). However, it has not been studied in conditions where the major abnormality is elevation of chylomicrons (i. e., hyperlipidemia Fredrickson types I and V). 4

Page:  << Prev | 1 | 2